- Review Article
- Open Access
The Egyptian Journal of Internal Medicine volume 26, pages 35–39 (2014)
Gout is a crystal deposition disease caused by raised levels of uric acid in the blood (hyperuricaemia) with persistence of hyperuricemia at levels higher than a serum saturation of 6.8 mg/dl leads to formation of monosodium urate (MSU) crystals and their deposition in joints and other tissues. However, only a minority of individuals with elevated serum uric acid (sUA) levels ever develop gout, emphasizing the importance of other factors in determining crystal formation including Genetics, Gender, age, Diet and alcohol intake, Obesity, some medications and medical conditions a correct diagnosis of gout is essential for the appropriate management, in 2011 the European League Against Rheumatism (EULAR) published an updated evidence based recommendations for diagnosis of gout. Although gout is well understood condition and good therapeutic options are available, it tends to be poorly managed, so The 2012 The American College of Rheumatology (ACR) guidelines for Management of Gout were designed to emphasize safety and quality of therapy and to reflect best practice. New approaches to urate lowering have led to mechanism-based therapies such as: non-purine, selective inhibitor of xanthine oxidase, URAT-1 inhibitors and a recombinant chimeric mammalian uricase. Three IL-1β antagonists — anakinra, rilonacept and canakinumab are being evaluated as an emerging therapies for gout.
M Doherty. New insights into the epidemiology of gout. Rheumatology 2009; 48: ii2–ii8.
Conway N, Schwartez S. Diagnosis and management of acute gout. Med Health R I 2009; 92: 356–358.
Mc Gill NW, Dieppe PA. The role of serum and synovial fluid components in the promotion of urate crystal formation. J Rheumatol 1991; 18: 1042–1045.
Lin KC, Lin HY, Chon P. The interaction between uric acid level and other risk factors in the development of gout among asymptomatic hyperuricemicmen in a prospective study. J Rheumatol 2000; 27: 1501–1505.
Graessler J, Graessler A, Unger S, et al. Association of the human uratetransporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 54: 292–300.
Le MT, Shatiu M, Mu W, Johnson RJ. SLC2A9 – a fructose transporter identified as a novel uric acid transporter. Nephrol Dial Transplant 2008; 23: 2746–2749.
Wallace K, Riedel A, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582–1587.
Choi H, Atkinson K, Karlson E, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093–1103.
Choi H, Atkinson K, Karlson E, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277–1281.
Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Br Med J 2008; 336: 309–312.
Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow up study. Arch Intern Med 2005; 165: 742–748.
KG Saag, H Choi. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006; 8: S2.
Richette P, Bardin T. Gout. Lancet 2010; 375: 318–328.
N Schlesinger. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005; 11 : S443–S450.
Dirken-Heuensfeldt KJ, Teunissen TA, Van de lisdonk EH, et al. Clinical features of women with gout arthritis: a systematic review. Clin Rheumatol 2010;29: 575–583.
Hamburger M, Baraf HS, Adamson TC III, Basile J, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sports Med 2011; 39: 98–123.
Khanna D, FitzGerald JD, Khanna PP, Bae S, Singh MK, Neogi N, et al. 2012 American College of Rheumatology guidelines for management of gou. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431–1446.
Khanna D, Khanna PP, FitzGerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gou. Part 2: Therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447–1461.
Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med 2013; 64: 325–337.
About this article
Cite this article
Rehim, H.A. Gout. Egypt J Intern Med 26, 35–39 (2014). https://doi.org/10.4103/1110-7782.139514
- recommendations for diagnosis and management